[250 Pages Report] The global Point-of-Care Cholesterol Monitoring Device Market was valued at US$ 428.8 Mn in 2021 and is expected to reach US$ 514.7 Mn by 2028, finds Future Market Insights (FMI) in a recent market survey.
Growing prevalence of target diseases like diabetes, cardiovascular diseases, and dyslipidemia is expected to be the primary factors driving the point-of-care cholesterol monitoring device market. Rising number of obesity and cardiovascular diseases leads to high blood cholesterol and lipoproteins levels, which increases the cholesterol testing requirement leading to growth of the market.
In addition, higher levels of cholesterol leads to buildup of cholesterol, fats and other substances on and around the artery walls, which is known as atherosclerosis. This further leads to conditions like stroke and heart attack, thus, increasing the demand for point-of-care cholesterol testing.
Point-of-care cholesterol monitoring device market holds nearly 5.6% market value share of the Diagnostics Market, which is around US$ 7.6 Bn in 2021. The adoption of these point-of-care devices is an economical way, it aids in early diagnosis and reduces the risk of further complications. Thus, the demand for point-of-care cholesterol monitoring kits and device is increasing nowadays.
Moreover, major players in the market are focusing on introduction of new technologically advanced testing kits and devices in order to increase their product portfolio.
For instance, in May 2021 DiaSys announced the availability of LDL-c direct FS, a new homogenous assay for direct determination of LDL-cholesterol (LDL-C).
Driven by this, sales of point-of-care cholesterol monitoring devices are expected to rise at a 2.6% CAGR through 2028.
Point-of-care Cholesterol Monitoring Device Market Outlook:
| Data Points | Market Insights |
|---|---|
| Market Value 2022 | USD 440.6 Million |
| Market Value 2028 | USD 514.7 Billion |
| CAGR 2022-2028 | 2.6% |
| Key Players | The key players are F. Hoffmann-La; Roche Ltd.; Abbott Laboratories; Abaxis, Inc. (Sub of Zoetis Inc.); DiaSys Diagnostic Systems GmbH; ACON Laboratories; PTS Diagnostics; Bioptik Technology, Inc.; SD; Biosensor, Inc.; Jant Pharmacal Corporation, Inc.; Nova Biomedical Corporation.; Beckman Coulter Inc. (Sub of Danaher Corporation) and SAMSUNG HEALTH CARE; Inc. |
| Share of Top 5 Countries | 54.5% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
| Particulars | Details |
|---|---|
| H1, 2021 | 2.61% |
| H1, 2022 Projected | 2.62% |
| H1, 2022 Outlook | 2.52% |
| BPS Change - H1, 2022 (O) - H1, 2022 (P) | (-) 10 ↓ |
| BPS Change - H1, 2022 (O) - H1, 2021 | (-) 9 ↓ |
The point-of-care cholesterol monitoring device market is subject to influence by rise in patient base with chronic disorders and technological developments in accordance with impact of macro and industry factors. As per the comparative analysis by Future Market Insights for market growth rate in 2022, a decreased value of 09 Basis Point Share (BPS) is expected in H1-2022 (O), when compared with H1-2021.
This owes to the relevance of the overall point-of-care diagnostics market as a whole in its nascent stages in developing regions, such as India. H1-2022 outlook period in comparison to H1-2022 projected period showed a negative growth in terms of Basis Point Share by 10 BPS.
Some factors involved in the increase of BPS include the rise in geriatric population having high level of High Density Lipoproteins (HDL) across the globe. Key players have been incorporating strategies of acquiring emerging players to strengthen their manufacturing facilities, as well increasing their investment in R&D in order to develop novel therapies.
Additionally, there has been rise in cholesterol testing at home and also increasing preference towards portable cholesterol detection devices.
Sales of point-of-care cholesterol monitoring device grew at a CAGR of 2.3% between 2013 and 2021.
Rising incidences of cardiovascular diseases and complications due to high cholesterol among the population is triggering the growth of the global point of care cholesterol monitoring device market. Also, the number of deaths because of cardiovascular diseases, and mortality because of the risk factors like smoking, excessive alcohol consumption, hyperlipidemia, hypercholesterolemia and obesity are rising globally.
As a result, there is growing awareness among the people regarding the benefits of the monitoring devices. In recent years, it is witnessed that governments around the world are taking initiatives to raise awareness associated to health problems. This, in turn, is expected to lead to the development of the market.
Moreover, the growing geriatric population is another factor driving the demand for the point-of-care cholesterol monitoring device market. The increasing old aged population is more prone to higher cholesterol level which is increasing the cholesterol related problems such as cardiovascular diseases. Therefore, the cholesterol testing products are increasing in the market for the forecast period.
In addition, advancements and development of smart & improved point of care cholesterol monitoring devices are expected to be the key factors driving the growth of the global market.
Considering this, FMI expects the global point-of-care cholesterol monitoring device market to grow at a CAGR of 2.6% through 2028.
The inaccurate and less reliable results obtained from point of care testing devices is the major factor limiting the growth of the global market. Point of care testing might be helpful in serious situations demanding rapid test results for clinical assessment. However, there are various limitations associated with point of care testing, primarily associated to quality assurance.
The tests carried out in laboratories are performed by trained professionals and ensure accurate results while point of care testing is usually done by untrained professionals as well as patients themselves. Hence, this may result in fluctuation of results due to less accuracy while performing the test, which in turn hampers the market growth.
In addition, stringent regulatory scenarios for new device approval is another factor that is challenging the growth of the market. Various amendments have been made by the regulatory bodies in the recent years to deal with the lack of standardization in device portfolio, which leads to long time period in product approvals, in turn hindering the point-of-care cholesterol monitoring device market.
Principal Consultant
Similar to other markets, negative effects of the COVID-19 crisis posed several challenges to the development of the diabetes point-of-care cholesterol monitoring device market also. Transportation restrictions and social distancing norms enforced by governments resulted into a shortage of raw materials and workers. This subsequently led to disruption of manufacturing activities through the initial stages of the pandemic.
Numerous international administrations issued health advisories to contain the spread of pandemic. Various initiatives undertaken to increase awareness by these organizations are anticipated to boost the market’s growth during the pandemic crisis. For example, the International Diabetes Federation has indicated that diabetic patients are more susceptible to becoming seriously ill if infected by the virus. Therefore, increasing health awareness and the association of COVID-19 with diabetes is expected to add to the growth of the market.
The U.S. is estimated to account for around 86.5% of the North America point-of-care cholesterol monitoring device market in 2022.
The rising incidence of cardiovascular disease and growing prevalence of high cholesterol increases the demand for the market. As per the data published by the CDC (Centers for Disease Control & Prevention), it was projected that approximately 34.2 million of the population were suffering from diabetes in the U.S. in 2020. Key manufacturers of point of care cholesterol monitoring devices in the market are focusing on increasing their portfolio by adding new product features to strengthen their position in the U.S.
Germany is estimated to account for 23.8% of the Europe Point-of-care Cholesterol Monitoring Device market in Europe in 2022.
The growth of the market in Germany is due to the initiatives undertaken by the government concerning to the expansion of healthcare infrastructure and, and presence of favorable regulations together with the high disease occurrence levels in the country. For instance, about 10% of the people in Germany suffer from diabetes, out of which 98% accounts for type 2 diabetes. Point-of-care monitoring is extensively used in developed nations due to better reimbursement policies and high awareness as compared to the emerging countries.
The Point-of-care Cholesterol Monitoring Device market in China is estimated to be worth US$ 38.2 Mn in 2022 in the global market.
The primary factors boosting the growth of the market include increasing technological advancement in monitoring devices together with growing adoption of inorganic growth strategies such as agreements and collaborations to manufacture novel devices. Moreover, increasing prevalence of diabetes is another factor supporting the development of the market in China.
Demand for Point-of-care Cholesterol Monitoring Device in India is expected to rise at around 3.0% CAGR over the forecast period.
The growing geriatric population and the increased awareness regarding cholesterol monitoring are some of the major factors that will lead the market development in India. The increasing old aged population is more prone to higher cholesterol level which is increasing the cholesterol related problems such as cardiovascular diseases.
As per the United Nations, report, there were above 138 million persons over 65 years or over of age in India in 2020. This count is expected to almost double by 2050.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
By Product, the testing kits segment is anticipated to hold the maximum share of 63.9% in 2022, expanding at rate of nearly 2.4% during the forecast period.
The segment is expected to further gain traction, owing to increasing adoption of point-of-care testing, availability of rapid testing kits and increased awareness regarding cholesterol monitoring.
The major benefit of point-of-care testing kits is that it does not need any clinical laboratory personnel to perform the test and the results are obtained rapidly. This rapid results can help in determination of the course of the treatment in case of emergency. These advantages of testing kits is anticipated to boost the demand for this segment.
In addition, several technological advancements in these testing kits such as the introduction of home testing kits is expected to add to the growth of the segment.
By technology, reflectance photometry segment will lead the market and is projected to account for 51.6% of the total market revenue share in 2022.
The benefits offered by reflectance photometry over other techniques is leading the segment growth. There are several advantages when the testing is done nearer to the patient rather than far away in a laboratory. In reflectance photometry just a small amount of blood is applied on a strip, then the plasma is removed and the strip is dissolved in the reagents, which results into coloration of the strip, indicating the result by showing the intensity. Hence, this is a rapid technique for cholesterol determination and is widely used.
In terms of application, atherosclerosis segment in projected to account for 32.3% of the total market share in 2022. The rising cases of atherosclerosis is the primary factor leading its rising market share.
Atherosclerosis is the accumulation of cholesterol, fats and other substances on the walls of the arteries. This leads to increase in risk of stroke and heart attack due to decrease in the blood flow to the heart muscles because of the narrowing of the arteries. Thus, the use of point of care cholesterol devices for monitoring of arthrosclerosis cases is leading to growth of the atherosclerosis segment among all applications.
By end user, the diagnostics centers & laboratory segment is anticipated to hold the maximum share of 33.7% in 2022, expanding at rapid rate of 2.3% CAGR during the forecast period.
The segment is growing owing to the well-established infrastructure, installation of technologically advanced analysis equipment and rising number of diagnostic centers and laboratories. In addition, growing awareness regarding early diagnosis of disease and increasing prevalence of cardiovascular diseases are some other factors driving the demand for the segment.
Companies operating in the point-of-care cholesterol monitoring device market are consolidated by nature, with a presence of few players holding major share. These players are involved in a number of strategic alliances. The product launch and acquisition accelerates the manufacturer’s strategy to capitalize on the market share and capture the significant share of market. Some of the recent instances include:
| Attribute | Details |
|---|---|
| Forecast Period | 2022 to 2028 |
| Historical Data Available for | 2013 to 2021 |
| Market Analysis | USD Million for Value |
| Key Countries Covered | USA, Canada, Brazil, Mexico, Germany, UK, France, Italy, Spain, Poland, Russia, China, Japan, South Korea, India, Thailand, Malaysia, Indonesia, Australia, New Zealand, GCC Countries, South Africa |
| Key Segments Covered | Product, Technology, Application, End User and Region |
| Key Companies Profiled | F.Hoffmann-La Roche Ltd.; Abbott Laboratories; Abaxis, Inc. (Sub of Zoetis Inc.); DiaSys Diagnostic Systems GmbH; ACON Laboratories; PTS Diagnostics; Bioptik Technology, Inc.; SD Biosensor, Inc.; Jant Pharmacal Corporation, Inc.; Nova Biomedical Corporation.; Beckman Coulter Inc. (Sub of Danaher Corporation); SAMSUNG HEALTH CARE, Inc. |
| Report Coverage | Market Forecast, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, Strategic Growth Initiatives |
| Customization & Pricing | Available upon Request |
The global point-of-care cholesterol monitoring device market is worth US$ 428.8 Mn in 2021 and is set to expand 1.2X over the forecasted years.
The sales of point-of-care cholesterol monitoring device in the market have grown at a CAGR of nearly 2.3% between 2013 and 2021.
The point-of-care cholesterol monitoring device market is expected to reach US$ 514.7 Mn by the end of 2028 with sales revenue expected to register CAGR of 2.6% over the forecast period.
North America is expected to dominate the global point-of-care cholesterol monitoring device market holding nearly 33.1% in 2022 of the global revenue share with U.S. being the leading contributor in this region having a market value of around US$ 126.2 Mn in 2022.
Demand of point-of-care cholesterol monitoring device market is expected to register growth in Asia Pacific at rate of 3.4% CAGR during the forecast period.
The point-of-care cholesterol monitoring device in China is likely to observe 1.3x growth during the forecast period with a growth rate of nearly 3.8% CAGR.
Increasing launch of new technological products, inclination towards portable devices, and increasing demand for home based testing for cholesterol are the key trends driving sales of point-of-care cholesterol monitoring device market across the globe.
India’s point-of-care cholesterol monitoring device market is offering lucrative growth opportunities and is expected to exhibit healthy growth of 3.0% CAGR during the forecast period. Japan market is expected to exhibit healthy growth of 3.0% CAGR during the forecast period.
U.S., China, Japan, Germany and U.K. are the top 5 countries that are driving the demand for point-of-care cholesterol monitoring device market.
Leading companies of Point-of-care Cholesterol Monitoring Device are F.Hoffmann-La, Roche Ltd., Abbott Laboratories, Abaxis, Inc. (Sub of Zoetis Inc.), DiaSys Diagnostic Systems GmbH, ACON Laboratories, PTS Diagnostics, Bioptik Technology, Inc., SD, Biosensor, Inc., Jant Pharmacal Corporation, Inc., Nova Biomedical Corporation., Beckman Coulter Inc. (Sub of Danaher Corporation) and SAMSUNG HEALTH CARE, Inc.
1. Executive Summary 1.1. Market Overview 1.2. Market Analysis 1.3. FMI Analysis and Recommendations 1.4. Wheel of Fortune 2. Market Introduction 2.1. Market Taxonomy 2.2. Market Definition 3. Global Point of Care Cholesterol Monitoring Device Market Opportunity Analysis 3.1. Macro-Economic Factors 3.2. Opportunity Analysis 4. Global Economic Outlook 4.1. Global Gross Domestic Product by Region & Country, 2017 – 2022 5. Market Background 5.1. Market Evolution 5.2. Market Dynamics 5.2.1. Drivers 5.2.2. Restraints 5.2.3. Market Trends 6. Key Inclusions 6.1. Consumer Adoption Process 6.2. List of Manufacturers 6.3. Epidemiology Study 7. North America Point of Care Cholesterol Monitoring Device Market Analysis 2013-2021 and Forecast 2022-2028 7.1. Introduction 7.2. Historical Market Size (US$ Mn) Analysis By Country, 2013-2021 7.2.1. U.S. 7.2.2. Canada 7.3. Market Size (US$ Mn) Forecast By Country, 2022-2028 7.4. Historical Market Value (US$ Mn) Analysis By Product, 2013-2021 7.4.1. Instruments 7.4.1.1. Table-top Analyzer 7.4.1.2. Hand-held Devices 7.4.2. Testing Kits 7.5. Market Value (US$ Mn) Forecast By Product, 2022-2028 7.6. Historical Market Value (US$ Mn) Analysis By Technology Type, 2013-2021 7.6.1. Electro chemical biosensor 7.6.2. Reflectance photometry 7.7. Market Value (US$ Mn) Forecast By Technology Type, 2022-2028 7.8. Historical Market Value (US$ Mn) Analysis By Application Type, 2013-2021 7.8.1. Dyslipidemia 7.8.2. Atherosclerosis 7.8.3. Hypercholesterolemia 7.8.4. Hypocholesterolemia 7.8.5. Others 7.9. Market Size (US$ Mn) Forecast By Application, 2022-2028 7.10. Market Size (US$ Mn) Forecast By End User, 2022-2028 7.11. Historical Market Value (US$ Mn) Analysis By End User, 2013-2021 7.11.1. Hospitals 7.11.2. Diagnostics centers & laboratory 7.11.3. Ambulatory surgical centers 7.11.4. Home care sittings 7.12. Market Size (US$ Mn) Forecast By End User, 2022-2028 7.13. Market Attractiveness Analysis 7.13.1. By Country 7.13.2. By Product 7.13.3. By Technology Type 7.13.4. By Application 7.13.5. By End User 7.14. Drivers and Restraints: Impact Analysis 7.15. Key Representative Participants Presence (Intensity Map) 8. Western Europe Point of Care Cholesterol Monitoring Device Market Analysis 2013-2021 and Forecast 2022-2028 8.1. Introduction 8.2. Historical Market Size (US$ Mn) Analysis By Country, 2013-2021 8.2.1. Germany 8.2.2. U.K 8.2.3. France 8.2.4. Italy 8.2.5. Spain 8.2.6. Rest of Western Europe 8.3. Market Size (US$ Mn) Forecast By Country, 2022-2028 8.4. Historical Market Value (US$ Mn) Analysis By Product, 2013-2021 8.4.1. Instruments 8.4.1.1. Table-top Analyzer 8.4.1.2. Hand-held Devices 8.4.2. Testing Kits 8.5. Market Value (US$ Mn) Forecast By Product, 2022-2028 8.6. Historical Market Value (US$ Mn) Analysis By Technology Type, 2013-2021 8.6.1. Electro chemical biosensor 8.6.2. Reflectance photometry 8.7. Market Value (US$ Mn) Forecast By Technology Type, 2022-2028 8.8. Historical Market Value (US$ Mn) Analysis By Application Type, 2013-2021 8.8.1. Dyslipidemia 8.8.2. Atherosclerosis 8.8.3. Hypercholesterolemia 8.8.4. Hypocholesterolemia 8.8.5. Others 8.9. Market Size (US$ Mn) Forecast By Application, 2022-2028 8.10. Market Size (US$ Mn) Forecast By End User, 2022-2028 8.11. Historical Market Value (US$ Mn) Analysis By End User, 2013-2021 8.11.1. Hospitals 8.11.2. Diagnostics centers & laboratory 8.11.3. Ambulatory surgical centers 8.11.4. Home care sittings 8.12. Market Size (US$ Mn) Forecast By End User, 2022-2028 8.13. Market Attractiveness Analysis 8.13.1. By Country 8.13.2. By Product 8.13.3. By Technology Type 8.13.4. By Application 8.13.5. By End User 8.14. Drivers and Restraints: Impact Analysis 8.15. Key Representative Participants Presence (Intensity Map) 9. Eastern Europe Point of Care Cholesterol Monitoring Device Market Analysis 2013-2021 and Forecast 2022-2028 9.1. Introduction 9.2. Historical Market Size (US$ Mn) Analysis By Country, 2013-2021 9.2.1. Russia 9.2.2. Poland 9.2.3. Rest of Eastern Europe 9.3. Market Size (US$ Mn) Forecast By Country, 2022-2028 9.4. Historical Market Value (US$ Mn) Analysis By Product, 2013-2021 9.4.1. Instruments 9.4.1.1. Table-top Analyzer 9.4.1.2. Hand-held Devices 9.4.2. Testing Kits 9.5. Market Value (US$ Mn) Forecast By Product, 2022-2028 9.6. Historical Market Value (US$ Mn) Analysis By Technology Type, 2013-2021 9.6.1. Electro chemical biosensor 9.6.2. Reflectance photometry 9.7. Market Value (US$ Mn) Forecast By Technology Type, 2022-2028 9.8. Historical Market Value (US$ Mn) Analysis By Application Type, 2013-2021 9.8.1. Dyslipidemia 9.8.2. Atherosclerosis 9.8.3. Hypercholesterolemia 9.8.4. Hypocholesterolemia 9.8.5. Others 9.9. Market Size (US$ Mn) Forecast By Application, 2022-2028 9.10. Market Size (US$ Mn) Forecast By End User, 2022-2028 9.11. Historical Market Value (US$ Mn) Analysis By End User, 2013-2021 9.11.1. Hospitals 9.11.2. Diagnostics centers & laboratory 9.11.3. Ambulatory surgical centers 9.11.4. Home care sittings 9.12. Market Size (US$ Mn) Forecast By End User, 2022-2028 9.13. Market Attractiveness Analysis 9.13.1. By Country 9.13.2. By Product 9.13.3. By Technology Type 9.13.4. By Application 9.13.5. By End User 9.14. Drivers and Restraints: Impact Analysis 9.15. Key Representative Participants Presence (Intensity Map) 10. Latin America Point of Care Cholesterol Monitoring Device Market Analysis 2013-2021 and Forecast 2022-2028 10.1. Introduction 10.2. Historical Market Size (US$ Mn) Analysis By Country, 2013-2021 10.3. Brazil 10.3.1. Mexico 10.3.2. Rest of Latin America 10.4. Market Size (US$ Mn) Forecast By Country, 2022-2028 10.5. Historical Market Value (US$ Mn) Analysis By Product, 2013-2021 10.5.1. Instruments 10.5.1.1. Table-top Analyzer 10.5.1.2. Hand-held Devices 10.5.2. Testing Kits 10.6. Market Value (US$ Mn) Forecast By Product, 2022-2028 10.7. Historical Market Value (US$ Mn) Analysis By Technology Type, 2013-2021 10.7.1. Electro chemical biosensor 10.7.2. Reflectance photometry 10.8. Market Value (US$ Mn) Forecast By Technology Type, 2022-2028 10.9. Historical Market Value (US$ Mn) Analysis By Application Type, 2013-2021 10.9.1. Dyslipidemia 10.9.2. Atherosclerosis 10.9.3. Hypercholesterolemia 10.9.4. Hypocholesterolemia 10.9.5. Others 10.10. Market Size (US$ Mn) Forecast By Application, 2022-2028 10.11. Market Size (US$ Mn) Forecast By End User, 2022-2028 10.12. Historical Market Value (US$ Mn) Analysis By End User, 2013-2021 10.12.1. Hospitals 10.12.2. Diagnostics centers & laboratory 10.12.3. Ambulatory surgical centers 10.12.4. Home care sittings 10.13. Market Size (US$ Mn) Forecast By End User, 2022-2028 10.14. Market Attractiveness Analysis 10.14.1. By Country 10.14.2. By Product 10.14.3. By Technology Type 10.14.4. By Application 10.14.5. By End User 10.15. Drivers and Restraints: Impact Analysis 10.16. Key Representative Participants Presence (Intensity Map) 11. Asia-Pacific Excluding Japan Point of Care Cholesterol Monitoring Device Market Analysis 2013-2021 and Forecast 2022-2028 11.1. Introduction 11.2. Historical Market Size (US$ Mn) Analysis By Country, 2013-2021 11.2.1. China 11.2.2. India 11.2.3. Australia and New Zealand 11.2.4. ASEAN 11.2.5. Rest of APEJ 11.3. Market Size (US$ Mn) Forecast By Country, 2022-2028 11.4. Historical Market Value (US$ Mn) Analysis By Product, 2013-2021 11.4.1. Instruments 11.4.1.1.1. Table-top Analyzer 11.4.1.1.2. Hand-held Devices 11.4.2. Testing Kits 11.5. Market Value (US$ Mn) Forecast By Product, 2022-2028 11.6. Historical Market Value (US$ Mn) Analysis By Technology Type, 2013-2021 11.6.1. Electro chemical biosensor 11.6.2. Reflectance photometry 11.7. Market Value (US$ Mn) Forecast By Technology Type, 2022-2028 11.8. Historical Market Value (US$ Mn) Analysis By Application Type, 2013-2021 11.8.1. Dyslipidemia 11.8.2. Atherosclerosis 11.8.3. Hypercholesterolemia 11.8.4. Hypocholesterolemia 11.8.5. Others 11.9. Market Size (US$ Mn) Forecast By Application, 2022-2028 11.10. Market Size (US$ Mn) Forecast By End User, 2022-2028 11.11. Historical Market Value (US$ Mn) Analysis By End User, 2013-2021 11.11.1. Hospitals 11.11.2. Diagnostics centers & laboratory 11.11.3. Ambulatory surgical centers 11.11.4. Home care sittings 11.12. Market Size (US$ Mn) Forecast By End User, 2022-2028 11.13. Market Attractiveness Analysis 11.13.1. By Country 11.13.2. By Product 11.13.3. By Technology Type 11.13.4. By Application 11.13.5. By End User 11.14. Drivers and Restraints: Impact Analysis 11.15. Key Representative Participants Presence (Intensity Map) 12. Japan Point of Care Cholesterol Monitoring Device Market Analysis 2013-2021 and Forecast 2022-2028 12.1. Introduction 12.2. Market Size (US$ Mn) Forecast By Country, 2022-2028 12.3. Historical Market Value (US$ Mn) Analysis By Product, 2013-2021 12.3.1. Instruments 12.3.1.1. Table-top Analyzer 12.3.1.2. Hand-held Devices 12.3.2. Testing Kits 12.4. Market Value (US$ Mn) Forecast By Product, 2022-2028 12.5. Historical Market Value (US$ Mn) Analysis By Technology Type, 2013-2021 12.5.1. Electro chemical biosensor 12.5.2. Reflectance photometry 12.6. Market Value (US$ Mn) Forecast By Technology Type, 2022-2028 12.7. Historical Market Value (US$ Mn) Analysis By Application Type, 2013-2021 12.7.1. Dyslipidemia 12.7.2. Atherosclerosis 12.7.3. Hypercholesterolemia 12.7.4. Hypocholesterolemia 12.7.5. Others 12.8. Market Size (US$ Mn) Forecast By Application, 2022-2028 12.9. Market Size (US$ Mn) Forecast By End User, 2022-2028 12.10. Historical Market Value (US$ Mn) Analysis By End User, 2013-2021 12.10.1. Hospitals 12.10.2. Diagnostics centers & laboratory 12.10.3. Ambulatory surgical centers 12.10.4. Home care sittings 12.11. Market Size (US$ Mn) Forecast By End User, 2022-2028 12.12. Market Attractiveness Analysis 12.12.1. By Country 12.12.2. By Product 12.12.3. By Technology Type 12.12.4. By Modality Type 12.12.5. By Application 12.12.6. By End User 12.13. Drivers and Restraints: Impact Analysis 12.14. Key Representative Participants Presence (Intensity Map) 13. Middle East and Africa Point of Care Cholesterol Monitoring Device Market Analysis 2013-2021 and Forecast 2022-2028 13.1. Introduction 13.2. Historical Market Size (US$ Mn) Analysis By Country, 2013-2021 13.2.1. GCC Countries 13.2.2. South Africa 13.2.3. Rest of MEA 13.3. Market Size (US$ Mn) Forecast By Country, 2022-2028 13.4. Historical Market Value (US$ Mn) Analysis By Product, 2013-2021 13.4.1. Instruments 13.4.1.1.1. Table-top Analyzer 13.4.1.1.2. Hand-held Devices 13.4.2. Testing Kits 13.5. Market Value (US$ Mn) Forecast By Product, 2022-2028 13.6. Historical Market Value (US$ Mn) Analysis By Technology Type, 2013-2021 13.6.1. Electro chemical biosensor 13.6.2. Reflectance photometry 13.7. Market Value (US$ Mn) Forecast By Technology Type, 2022-2028 13.8. Historical Market Value (US$ Mn) Analysis By Application Type, 2013-2021 13.8.1. Dyslipidemia 13.8.2. Atherosclerosis 13.8.3. Hypercholesterolemia 13.8.4. Hypocholesterolemia 13.8.5. Others 13.9. Market Size (US$ Mn) Forecast By Application, 2022-2028 13.10. Market Size (US$ Mn) Forecast By End User, 2022-2028 13.11. Historical Market Value (US$ Mn) Analysis By End User, 2013-2021 13.11.1. Hospitals 13.11.2. Diagnostics centers & laboratory 13.11.3. Ambulatory surgical centers 13.11.4. Home care sittings 13.12. Market Size (US$ Mn) Forecast By End User, 2022-2028 13.13. Market Attractiveness Analysis 13.13.1. By Country 13.13.2. By Product 13.13.3. By Technology Type 13.13.4. By Application 13.13.5. By End User 13.14. Drivers and Restraints: Impact Analysis 13.15. Key Representative Participants Presence (Intensity Map) 14. Forecast Factors: Relevance and Impact 15. Forecast Assumptions 16. Competition Analysis 16.1. Competition Dashboard 16.2. Competitors Deep Dive 16.2.1. ACON Laboratories, Inc. 16.2.1.1. Overview 16.2.1.2. Product and Modality Portfolio 16.2.1.3. Production Footprint 16.2.1.4. Sales Footprint 16.2.1.5. Channel Footprint 16.2.1.6. Strategy 16.2.1.6.1. Marketing Strategy 16.2.1.6.2. Product Strategy 16.2.1.6.3. Channel Strategy 16.2.2. DiaSys Diagnostic Systems GmbH. 16.2.2.1. Overview 16.2.2.2. Product and Modality Portfolio 16.2.2.3. Production Footprint 16.2.2.4. Sales Footprint 16.2.2.5. Channel Footprint 16.2.2.6. Strategy 16.2.2.6.1. Marketing Strategy 16.2.2.6.2. Product Strategy 16.2.2.6.3. Channel Strategy 16.2.3. Roche Diagnostics 16.2.3.1. Overview 16.2.3.2. Product and Modality Portfolio 16.2.3.3. Production Footprint 16.2.3.4. Sales Footprint 16.2.3.5. Channel Footprint 16.2.3.6. Strategy 16.2.3.6.1. Marketing Strategy 16.2.3.6.2. Product Strategy 16.2.3.6.3. Channel Strategy 16.2.4. Home Health Ltd. 16.2.4.1. Overview 16.2.4.2. Product and Modality Portfolio 16.2.4.3. Production Footprint 16.2.4.4. Sales Footprint 16.2.4.5. Channel Footprint 16.2.4.6. Strategy 16.2.4.6.1. Marketing Strategy 16.2.4.6.2. Product Strategy 16.2.4.6.3. Channel Strategy 16.2.5. SD Biosensor, INC 16.2.5.1. Overview 16.2.5.2. Product and Modality Portfolio 16.2.5.3. Production Footprint 16.2.5.4. Sales Footprint 16.2.5.5. Channel Footprint 16.2.5.6. Strategy 16.2.5.6.1. Marketing Strategy 16.2.5.6.2. Product Strategy 16.2.5.6.3. Channel Strategy 16.2.6. Alere Inc. 16.2.6.1. Overview 16.2.6.2. Product and Modality Portfolio 16.2.6.3. Production Footprint 16.2.6.4. Sales Footprint 16.2.6.5. Channel Footprint 16.2.6.6. Strategy 16.2.6.6.1. Marketing Strategy 16.2.6.6.2. Product Strategy 16.2.6.6.3. Channel Strategy 16.2.7. Abaxis Inc. 16.2.7.1. Overview 16.2.7.2. Product and Modality Portfolio 16.2.7.3. Production Footprint 16.2.7.4. Sales Footprint 16.2.7.5. Channel Footprint 16.2.7.6. Strategy 16.2.7.6.1. Marketing Strategy 16.2.7.6.2. Product Strategy 16.2.7.6.3. Channel Strategy 16.2.8. Polymer Technology Systems, Inc. 16.2.8.1. Overview 16.2.8.2. Product and Modality Portfolio 16.2.8.3. Production Footprint 16.2.8.4. Sales Footprint 16.2.8.5. Channel Footprint 16.2.8.6. Strategy 16.2.8.6.1. Marketing Strategy 16.2.8.6.2. Product Strategy 16.2.8.6.3. Channel Strategy 16.2.9. BIOPTIK LTD. 16.2.9.1. Overview 16.2.9.2. Product and Modality Portfolio 16.2.9.3. Production Footprint 16.2.9.4. Sales Footprint 16.2.9.5. Channel Footprint 16.2.9.6. Strategy 16.2.9.6.1. Marketing Strategy 16.2.9.6.2. Product Strategy 16.2.9.6.3. Channel Strategy 16.2.10. OSANG HEALTHCARE CO., LTD. 16.2.10.1. Overview 16.2.10.2. Product and Modality Portfolio 16.2.10.3. Production Footprint 16.2.10.4. Sales Footprint 16.2.10.5. Channel Footprint 16.2.10.6. Strategy 16.2.10.6.1. Marketing Strategy 16.2.10.6.2. Product Strategy 16.2.10.6.3. Channel Strategy 16.2.11. Fitech UK Ltd, 16.2.11.1. Overview 16.2.11.2. Product and Modality Portfolio 16.2.11.3. Production Footprint 16.2.11.4. Sales Footprint 16.2.11.5. Channel Footprint 16.2.11.6. Strategy 16.2.11.6.1. Marketing Strategy 16.2.11.6.2. Product Strategy 16.2.11.6.3. Channel Strategy 16.2.12. PRIMA Lab SA 16.2.12.1. Overview 16.2.12.2. Product and Modality Portfolio 16.2.12.3. Production Footprint 16.2.12.4. Sales Footprint 16.2.12.5. Channel Footprint 16.2.12.6. Strategy 16.2.12.6.1. Marketing Strategy 16.2.12.6.2. Product Strategy 16.2.12.6.3. Channel Strategy 16.2.13. Chematics, Inc. 16.2.13.1. Overview 16.2.13.2. Product and Modality Portfolio 16.2.13.3. Production Footprint 16.2.13.4. Sales Footprint 16.2.13.5. Channel Footprint 16.2.13.6. Strategy 16.2.13.6.1. Marketing Strategy 16.2.13.6.2. Product Strategy 16.2.13.6.3. Channel Strategy 16.2.14. Solana Health Inc. 16.2.14.1. Overview 16.2.14.2. Product and Modality Portfolio 16.2.14.3. Production Footprint 16.2.14.4. Sales Footprint 16.2.14.5. Channel Footprint 16.2.14.6. Strategy 16.2.14.6.1. Marketing Strategy 16.2.14.6.2. Product Strategy 16.2.14.6.3. Channel Strategy 16.2.15. AccuTech, LLC 16.2.15.1. Overview 16.2.15.2. Product and Modality Portfolio 16.2.15.3. Production Footprint 16.2.15.4. Sales Footprint 16.2.15.5. Channel Footprint 16.2.15.6. Strategy 16.2.15.6.1. Marketing Strategy 16.2.15.6.2. Product Strategy 16.2.15.6.3. Channel Strategy
Explore Healthcare Insights
View Reports
Point-of-care Cholesterol Monitoring Device Market
